JP2019534706A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534706A5
JP2019534706A5 JP2019520386A JP2019520386A JP2019534706A5 JP 2019534706 A5 JP2019534706 A5 JP 2019534706A5 JP 2019520386 A JP2019520386 A JP 2019520386A JP 2019520386 A JP2019520386 A JP 2019520386A JP 2019534706 A5 JP2019534706 A5 JP 2019534706A5
Authority
JP
Japan
Prior art keywords
antibody
drug conjugate
seq
heavy chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019520386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534706A (ja
JP7039577B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/056093 external-priority patent/WO2018073680A1/en
Publication of JP2019534706A publication Critical patent/JP2019534706A/ja
Publication of JP2019534706A5 publication Critical patent/JP2019534706A5/ja
Priority to JP2021190070A priority Critical patent/JP7383682B2/ja
Application granted granted Critical
Publication of JP7039577B2 publication Critical patent/JP7039577B2/ja
Priority to JP2023191037A priority patent/JP2023184697A/ja
Priority to JP2025146227A priority patent/JP2025175010A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019520386A 2016-10-17 2017-10-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート Active JP7039577B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021190070A JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2023191037A JP2023184697A (ja) 2016-10-17 2023-11-08 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2025146227A JP2025175010A (ja) 2016-10-17 2025-09-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409081P 2016-10-17 2016-10-17
US62/409,081 2016-10-17
PCT/IB2017/056093 WO2018073680A1 (en) 2016-10-17 2017-10-03 Anti-edb antibodies and antibody-drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021190070A Division JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Publications (3)

Publication Number Publication Date
JP2019534706A JP2019534706A (ja) 2019-12-05
JP2019534706A5 true JP2019534706A5 (enExample) 2020-11-12
JP7039577B2 JP7039577B2 (ja) 2022-03-22

Family

ID=60117722

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019520386A Active JP7039577B2 (ja) 2016-10-17 2017-10-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2021190070A Active JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2023191037A Pending JP2023184697A (ja) 2016-10-17 2023-11-08 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2025146227A Pending JP2025175010A (ja) 2016-10-17 2025-09-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021190070A Active JP7383682B2 (ja) 2016-10-17 2021-11-24 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2023191037A Pending JP2023184697A (ja) 2016-10-17 2023-11-08 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
JP2025146227A Pending JP2025175010A (ja) 2016-10-17 2025-09-03 抗ｅｄｂ抗体および抗体－薬物コンジュゲート

Country Status (22)

Country Link
US (5) US20190269791A1 (enExample)
EP (3) EP3525828B1 (enExample)
JP (4) JP7039577B2 (enExample)
KR (1) KR102338660B1 (enExample)
CN (2) CN110087691B (enExample)
AU (3) AU2017344440B2 (enExample)
CA (1) CA3040423A1 (enExample)
DK (1) DK3525828T3 (enExample)
ES (1) ES3007557T3 (enExample)
FI (1) FI3525828T3 (enExample)
HR (1) HRP20250056T1 (enExample)
HU (1) HUE070615T2 (enExample)
IL (2) IL310865A (enExample)
LT (1) LT3525828T (enExample)
MX (2) MX2019004434A (enExample)
PL (1) PL3525828T3 (enExample)
PT (1) PT3525828T (enExample)
RS (1) RS66524B1 (enExample)
RU (1) RU2758632C2 (enExample)
SG (1) SG11201903400WA (enExample)
SI (1) SI3525828T1 (enExample)
WO (1) WO2018073680A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
JP7514836B2 (ja) * 2018-12-12 2024-07-11 ブリストル－マイヤーズ スクイブ カンパニー トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
KR102614063B1 (ko) 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
CN112816453B (zh) * 2021-02-09 2022-07-08 黑龙江大学 蛋白在预测药物性能上的应用
US20240252662A1 (en) * 2021-05-20 2024-08-01 Case Western Reserve University Peptide drug conjugates specific to fibronectin isotypes for cancer therapy
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
IL316032A (en) 2022-04-08 2024-11-01 Regeneron Pharma Multicomponent receptor and signaling complexes
EP4716555A1 (en) * 2023-07-10 2026-04-01 Wuxi Xdc Singapore Private Limited Antibody-drug conjugates and production thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025208105A1 (en) * 2024-03-29 2025-10-02 Pyxis Oncology, Inc. Constructs, compositions, and methods for treating extra domain b splice variant of fibronectin-expressing diseases and disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5952329A (en) 1996-01-23 1999-09-14 The General Hospital Corporation Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
AU4243201A (en) 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
PT1257297E (pt) * 2000-02-24 2006-12-29 Philogen Spa Composições e método para tratamento da angiogénese em lesões patológicas
CA2445898A1 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
EP2239274A1 (en) * 2002-01-03 2010-10-13 Bayer Schering Pharma AG New methods for diagnosis and treatment of tumours
JP2005534283A (ja) 2002-03-11 2005-11-17 フィロジェン ソチエタ ペル アツィオニ 抗体分子を用いての腫瘍脈管系の選択的標的化
WO2004012735A2 (en) * 2002-07-31 2004-02-12 Schering Ag New effector conjugates, process for their production and their pharmaceutical use
US7314622B2 (en) 2005-04-15 2008-01-01 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
KR101281208B1 (ko) * 2005-05-11 2013-07-26 필로겐 에스.피.에이. 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질
CA2624667C (en) 2005-10-05 2018-01-09 Commonwealth Scientific And Industrial Research Organisation Silk proteins containing coiled coil region
EP1842553A1 (en) * 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
EP2015775B1 (en) * 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
TWI412367B (zh) * 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
JP5221641B2 (ja) 2007-04-02 2013-06-26 フィロゲン エスピーエー 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原
CN101754978B (zh) 2007-07-25 2013-06-05 菲洛根股份公司 一种与肺癌和淋巴瘤相关的抗原
ES2382058T3 (es) * 2008-01-17 2012-06-04 Philogen S.P.A. Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
EP3243527B1 (en) * 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP2947096B1 (en) 2009-08-05 2018-11-28 Philogen S.p.A. Targeting of bone marrow neovasculature
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
KR101436222B1 (ko) * 2009-12-14 2014-09-01 쉴 프로테인즈 게엠베하 리간드 결합능력을 가진 헤테로-다량체 변형 유비퀴틴 단백질을 확인하는 방법
WO2012041451A1 (en) 2010-09-29 2012-04-05 Philogen S.P.A. Thiazolidine linker for the conjugation of drugs to antibodies
CA2930801C (en) * 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
TWI589592B (zh) 2011-11-17 2017-07-01 輝瑞股份有限公司 胞毒性肽類以及其抗體藥物共軛體
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CA2900755C (en) * 2013-02-08 2021-07-20 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
WO2014174105A1 (en) * 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
CA2937731C (en) * 2014-01-27 2019-09-24 Pfizer Inc. Bifunctional cytotoxic agents
WO2015114166A2 (en) * 2014-02-03 2015-08-06 Philochem Ag Targeted drug conjugates
CN106456798B (zh) * 2014-04-25 2021-02-12 瑞纳神经科学公司 具有高药物负载的抗体-药物缀合物
CN113698488A (zh) * 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
TWI703160B (zh) * 2015-11-30 2020-09-01 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段

Similar Documents

Publication Publication Date Title
US11833120B2 (en) Binding protein drug conjugates comprising anthracycline derivatives
Richards Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery
ES2595091T3 (es) Composiciones farmacéuticas con resistencia a CEA soluble
JP2021532831A5 (enExample)
WO2019170131A1 (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
BR112021011014A2 (pt) Anticorpos anti-claudina e usos destes
JP2018509908A5 (enExample)
CN110869393A (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
JP2019531084A5 (enExample)
JP2016503295A5 (enExample)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
JP2017535246A5 (enExample)
WO2012047724A4 (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
JP7553633B2 (ja) Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
RU2016150377A (ru) Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc
JP2016531915A5 (enExample)
HRP20231609T1 (hr) Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2
JP2016512832A5 (enExample)
JP2016518332A5 (enExample)
RU2016139340A (ru) Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой
JP2010535713A5 (enExample)
FI3525828T3 (fi) Anti-edb-vasta-aineita ja vasta-aine-lääke-konjugaatteja
JP2013519364A5 (enExample)
JP2020504607A5 (enExample)
US20250302977A1 (en) Antibody-drug conjugates comprising humanized antibodies targeting urokinase type plasminogen activator receptor associated protein (uparap)